eThe transmissible spongiform encephalopathies are fatal neurodegenerative disorders characterized by the misfolding of the native cellular prion protein (PrP C ) into the accumulating, disease-associated isoform (PrP Sc ). Despite extensive research into the inhibition of prion accumulation, no effective treatment exists. Previously, we demonstrated the inhibitory activity of DB772, a monocationic phenyl-furan-benzimidazole, against PrP Sc accumulation in sheep microglial cells. In an effort to determine the effect of structural substitutions on the antiprion activity of DB772, we employed an in vitro strategy to survey a library of structurally related, monothiophene-and furan-based compounds for improved inhibitory activity. Eighty-nine compounds were screened at 1 M for effects on cell viability and prion accumulation in a persistently infected ovine microglia culture system. Eleven compounds with activity equivalent to or higher than that of DB772 were identified as preliminary hit compounds. For the preliminary hits, cytotoxicities and antiprion activities were compared to calculate the tissue culture selectivity index. A structure-activity relationship (SAR) analysis was performed to determine molecular components contributing to antiprion activity. To investigate potential mechanisms of inhibition, effects on PrP C and PrP Sc were examined. While inhibition of total PrP C was not observed, the results suggest that a potential target for inhibition at biologically relevant concentrations is through PrP C misfolding to PrP Sc . Further, SAR analysis suggests that two structural elements were associated with micromolar antiprion activity. Taken together, the described data provide a foundation for deeper investigation into untested DB compounds and in the design of effective therapeutics. P rions are unique proteinaceous, infectious agents that cause fatal neurodegenerative disorders collectively known as the transmissible spongiform encephalopathies (TSEs). TSEs include Creutzfeldt-Jakob disease in humans, chronic wasting disease in cervids, and scrapie in sheep and goats (1, 2). Prions are comprised of protease-resistant, disease-associated isoforms (PrP Sc ) of the prion protein (3). Prion protein in its native cellular form (PrP C ) is a glycoprotein encoded by the host's PRNP gene and is highly expressed in multiple cell types, including neurons, microglia, and certain cells of the immune system (1-3). Misfolding to PrP Sc promotes self-templated replication and accumulation within the central nervous system that lead to slowly progressive neurological dysfunction and eventually death (1-3). Currently, the mechanisms underlying this conversion are incompletely defined, and treatments to prevent or cure disease do not exist (4).Due to the invariable lethality of prion disease, identification of compounds that prevent misfolding, replication, or accumulation is a vital goal (4-6). Previous studies to screen candidate antiprion compounds have primarily employed rodent cell culture systems chronically infe...